SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Pfost Dale R

(Last)

(First)

(Middle)

EXEGENICS INC.

4400 BISCAYNE BOULEVARD, SUITE 900

(Street)

MIAMI

33137

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/29/2007

3. Issuer Name and Ticker or Trading Symbol
eXegenics Inc [ EXEG ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, $.01 par value	1,687,261	D⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series C Convertible Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	518,900	$0	D
Warrant (Right to Buy)	⁽³⁾	03/27/2017	Common Stock	64,868	$0.002	D
Warrant (Right to Buy)	⁽³⁾	03/27/2017	Common Stock	68,852	$0.6728	D
Warrant (Right to Buy)	⁽³⁾	03/27/2017	Common Stock	68,852	$0.8473	D
Warrant (Right to Buy)	⁽³⁾	03/27/2017	Common Stock	68,852	$1.0466	D
Stock Option (Right to Buy)	⁽⁴⁾	09/24/2014	Series C Convertible Preferred Stock	7,317	$31.8	D
Stock Option (Right to Buy)	⁽⁵⁾	12/11/2013	Common Stock	430,722	$0.04	D
Stock Option (Right to Buy)	⁽⁴⁾	09/24/2014	Common Stock	225,740	$0.04	D
Stock Option (Right to Buy)	⁽⁶⁾	02/15/2015	Common Stock	1,297,357	$0.04	D
Stock Option (Right to Buy)	⁽⁷⁾	11/01/2015	Common Stock	311,365	$0.05	D
Stock Option (Right to Buy)	⁽⁸⁾	01/01/2016	Common Stock	311,365	$0.05	D

Explanation of Responses:

1. 1,081,116 of these shares are owned jointly by Mr. Pfost and his wife.

2. These shares are currently exercisable and do not expire.

3. These warrants are currently exercisable.

4. These options are fully vesed.

5. 349,657 of these options are presently fully vested. The balance will vest monthly until fully vested in December 2007.

6. 675,705 of these options are presently fully vested. The balance will vest monthly until fully vested in February 2009..

7. 103,785 of these options are presently fully vested. The balance will vest monthly until fully vested in November 2009.

8. 90,814 of these options are presently fully vested. The balance will vest monthly until fully vested in January 2010.

Remarks:

All securities described were acquired in a merger transaction between Acuity Pharmaceuticals Inc. and eXegenics Inc.

	/s/ Dale R. Pfost	03/30/2007
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.